INTERIM BIOMARKER ANALYSIS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF SIBEPRENLIMAB (VIS649) IN PARTICIPANTS WITH IMMUNOGLOBULIN A NEPHROPATHY
Back
Abstract Number
WCN23-0684
Categories
AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
Topic - Chronic Kidney Disease, Hypertension, Diabetes and CVD
Topic - AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
Clinical Glomerulonephritis
Topic - Kidney Failure (Former ESKD), incl. Dialysis, Transplantation, Conservative Care
Topic - Special Covid-19
Topic - Education
Abstract Title
INTERIM BIOMARKER ANALYSIS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF SIBEPRENLIMAB (VIS649) IN PARTICIPANTS WITH IMMUNOGLOBULIN A NEPHROPATHY
Co-authors
Chan, D.T.M.(1)*;Kanjanabuch, T.(2);Liew, A.(3);Mathur, M.(4);Yarbrough, J.(5);Wang, X.(6);Suzuki , Y.(7)
ie:
Azwin Z.1, Siti Y.1, John D.2
Institution
(1)The University Of Hong Kong- Department Of Medicine- Queen Mary Hospital, Department Of Medicine, Hong Kong, Hong Kong- China;(2)Chulalongkorn University, Department Of Medicine- Division Of Nephrology, Bangkok, Thailand;(3)Mount Elizabeth Novena Hospital, The Kidney & Transplant Practice, Singapore, Singapore;(4)Visterra Inc, Clinical Development, Waltham- Massachusetts, United States;(5)Visterra Inc, Clinical Operations, Waltham- Massachusetts, United States;(6)Otsuka Pharmaceutical Development & Commercialization- Inc., Pharmacometrics, Princeton- New Jersey, United States;(7)Juntendo University, Department Of Nephrology, Tokyo, Japan
E-Poster
https://storage.unitedwebnetwork.com/files/1041/2ad376e019d4c39946392c98578e4dd6.pdf
Audio File
https://storage.unitedwebnetwork.com/files/1041/a1e5109f27098ca5a156cce36370fd00.mp3
if any